Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Aurobindo-Pharma"

85 News Found

Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma
News | September 08, 2023

Briefs: NATCO Pharma, Strides Pharma and Aurobindo Pharma

Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.


Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr
News | August 13, 2023

Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr

Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023


Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
Drug Approval | August 06, 2023

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated


Aurobindo Pharma gets 3 observations from USFDA for Unit 3 at Bachupally Village
Drug Approval | July 24, 2023

Aurobindo Pharma gets 3 observations from USFDA for Unit 3 at Bachupally Village

Aurobindo will respond to the US FDA within the stipulated timelines


Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr
News | May 29, 2023

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore


MMP Industries wins its first commercial order from Aurobindo Pharma
News | March 31, 2023

MMP Industries wins its first commercial order from Aurobindo Pharma

The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year


Aurobindo Pharma gets VAI classification from USFDA for Telangana plant
News | February 16, 2023

Aurobindo Pharma gets VAI classification from USFDA for Telangana plant

Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated


Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
News | February 10, 2023

Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores

Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.


Aurobindo Pharma receives 10 observations for Unit IX
Drug Approval | November 21, 2022

Aurobindo Pharma receives 10 observations for Unit IX

The company had responded to the agency and carried out the required corrective actions.


Aurobindo Pharma Q2 FY23 revenue down 3.4%
News | November 14, 2022

Aurobindo Pharma Q2 FY23 revenue down 3.4%

Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore